

## **REMARKS**

Upon entry of this amendment, Claims 1-23 are pending and under consideration. Claims 1-23 are original claims.

Group I has been elected, without traverse. Claims 7-23 are withdrawn from consideration.

### **i. Restriction and Election under 35 U.S.C. 121**

#### **a. Restriction of Groups I(a)**

The Office has made a restriction requirement between the following groups:

**Group 1(a).** Claims 1-6, drawn to a recombinant anticoagulant protein and a method of inhibiting blood coagulation utilizing said protein.

**Group 1(b).** Claim 10, drawn to a method of treating or preventing an excess thrombotic activity in a subject utilizing said protein.

Additionally, each of the inventions of Groups 1(a), 1(b) and II are directed to the following 4 distinct species.

- (1) SEQ ID NO: 1 or DNA encoding it.
- (2) SEQ ID NO: 2 or DNA encoding it.
- (3) SEQ ID NO: 3 or DNA encoding it.
- (4) SEQ ID NO: 4 or DNA encoding it.

The Office states that in order to be fully compliant to this requirement, the response must include (i) election of a species from Groups 1-4 above or invention from Groups 1(a-b) above to be examined, and (ii) identification of the claims encompassing the elected invention.

#### **b. Election of Groups I(a), without Traverse.**

With this response, the Applicants elect Group 1(a) without traverse, which encompasses Claims 1-6. Claims 7-9 and 11-23 are hereby withdrawn from consideration.

## II. CONCLUSION

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

Dated: December 13, 2007

/G. Harley Blosser/

G. Harley Blosser, Reg. No. 33,650  
Customer No. 26263  
314.259.5806